Vistagen Therapeutics, Inc.
For the period ended Jun 15, 2026. Filed Jun 15, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Jun 15, 2026 · Filed Jun 15, 2026
Use the contents to explore the available documents and sections.
VTGN$0.16-0.8%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · (in thousands, except share and per share data)
(in thousands, except share and per share data)
| Year EndedMarch 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Revenues: | ||
| Sublicense and other revenue | $1,269 | $486 |
| Total revenues | 1,269 | 486 |
| Operating expenses: | ||
| Research and development | 54,974 | 39,375 |
| General and administrative | 18,421 | 17,084 |
| Total operating expenses | 73,395 | 56,459 |
| Loss from operations | (72,126) | (55,973) |
| Other income, net: | ||
| Interest income, net | 2,441 | 4,557 |
| Other income, net | 7 | 5 |
| Loss before income taxes | (69,678) | (51,411) |
| Income taxes | (7) | (7) |
| Net loss | $(69,685) | $(51,418) |
| Unrealized gain (loss) on marketable securities | $(7) | $5 |
| Comprehensive loss | $(69,692) | $(51,413) |
| Basic and diluted net loss per common share | $(1.83) | $(1.67) |
| Weighted average common shares outstanding, basic and diluted | 38,073,926 | 30,877,029 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.